13F Holdings
中文EN

SYBX SYNLOGIC, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1527599 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-99.8%
TTM net income YoY59.2%
TTM EPS YoY79.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-511,875.0%
Net margin-291,987.5%
FCF margin-395,900.0%
EBITDA margin-507,537.5%

Returns

ROE-102.6%
ROA-49.0%
ROIC (approx.)-2,394.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets35.7%
Debt / equity0.00x
Current ratio2.80x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.36x
Accruals ratio17.4%
Payout ratio—
Capex / revenue175.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$8,000$3.37M$1.18M$1.75M
R&D expense$43,000$9.15M$43.97M$52.04M$47.13M
SG&A expense$3.49M$6.63M$14.56M$16.55M$15.39M
Operating income-$4.01M-$40.95M-$55.16M-$67.42M-$60.77M
Interest expense—$0$1,000$2,000$2,000
Pretax income-$1.00M-$23.35M-$61.26M-$66.15M—
Income tax$0$5,000$14,000$0$0
Net income-$1.00M-$23.36M-$61.27M-$66.15M-$60.56M
EBITDA-$4.01M-$40.60M-$53.20M-$64.90M-$58.32M
EPS (basic)-0.08-1.92-9.42-13.83-1.09
EPS (diluted)-0.08-1.92-9.42-13.83-1.09
Weighted avg. shares (diluted)12.31M12.20M6.50M4.78M55.33M
Balance sheet
Cash & equivalents$14.67M$18.86M$23.96M$15.86M$16.44M
Short-term investments—$0$23.79M$61.77M$112.15M
Current assets$15.40M$19.78M$49.91M$79.78M$133.31M
PP&E, net—$0$5.60M$7.32M$9.09M
Total assets$15.45M$19.83M$75.55M$110.86M$174.74M
Current liabilities$3.58M$7.08M$30.29M$12.12M$10.08M
Total liabilities$3.58M$7.08M$42.78M$28.25M$27.47M
Shareholders' equity$11.86M$12.75M$32.77M$82.61M$147.27M
Shares outstanding11.70M11.70M9.19M4.45M69.70M
Cash flow statement
Operating cash flow-$4.36M-$31.66M-$51.61M-$56.89M-$52.20M
Capital expenditure$0$14,000$214,000$728,000$679,000
Free cash flow-$4.36M-$31.67M-$51.83M-$57.62M-$52.88M
Investing cash flow$167,000$25.34M$38.77M$58.35M-$53.25M
Financing cash flow$0$172,000$20.94M-$2.04M$89.38M
Depreciation & amortization$0$347,000$1.96M$2.52M$2.44M
Stock-based compensation$117,000$3.17M$2.81M$3.64M$3.36M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.